DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT04964388

TerminatedPhase 2Results posted

Effect of GLP-1 Receptor Agonists on Trabecular Bone Score

Effect of GLP-1 Receptor Agonists on Trabecular Bone Score and Visceral Adiposity in Postmenopausal Women With Type 2 Diabetes Mellitus.

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

—

Enrollment

5

actual

Study population

Osteoporosis / bone, Type 2 diabetes

Key I/E criteria

•HbA1c 7-10%•Female

Primary endpoint

•Trabecular Bone Score

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04964388
Org study IDUMississippi

Timeline

Milestones

Study first posted2021-07-16actual
Study start2021-11-09actual
Primary completion2023-05-01actual
Study completion2023-07-01actual
Results first posted2024-07-24actual
Last update posted2025-06-13actual

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Osteoporosis / boneType 2 diabetes

Eligibility

Who can enroll

Minimum age55 Years
SexFemale
Healthy volunteersNot accepted

Inclusion criteria

•Diagnosis of Type 2 Diabetes Mellitus
•Postmenopausal female
•Age >55 years
•Hemoglobin A1c between 7-10% within 6 months of the first visit.

Exclusion criteria

•Patients with type 1 Diabetes mellitus
•Patients with a history of GLP-1 receptor agonist/DPP4 inhibitor use
•eGFR <30 ml/min in the last 3 months
•Patients with a history of pancreatitis
•Personal or family history of medullary thyroid cancer
•Patients with a history of treatment with anti-osteoporosis agents
•Documented secondary osteoporosis
•Documented presence of prosthesis or devices in the spine
•Unwilling or unable to consent

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
2
Weight & body composition
1
Other clinical outcomes
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint

Visceral Fat Mass

Time frame:12 months after index date

Visceral fat, change

change from baseline, improvement

Other clinical outcomes

1 endpoint
Primary/protocol endpoint

Trabecular Bone Score

Time frame:12 months after index date

change from baseline, improvement

Other (unclassified)

2 endpoints
Secondary/protocol endpoint/low confidence

Inflammatory Markers and Bone Resorption Markers

Time frame:12 months after index date

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Sclerostin and Bone Formation Markers

Time frame:12 months after index date

change from baseline, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.